Asset profile
ALKS 2680
Small molecule
Evidence outlook · registrational
Narcolepsy: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-05.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
4 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 4 same-indication; 3 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| ALKS 2680: this drug | Phase 3 | Small molecule | — | ||
| Pitolisant (Wakix) | Approved | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | ||
| Sodium Oxybate | Approved | Small molecule | GABA-B receptor | ||
| Solriamfetol (Sunosi) | Approved | Small molecule | Dopamine/norepinephrine transporter | ||
| Reboxetine | Phase 3 | Small molecule | norepinephrine transporter |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
2027 (3)
May 2027 (2)
June 2027 (1)
2028 (1)
June 2028 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.